Upgrade to SI Premium - Free Trial

Amgen (AMGN) Says New Data Shows Aimovig Reduced Monthly Migraine Days In Patients Who Failed Previous Preventive Therapies

September 7, 2017 4:31 PM
Amgen (NASDAQ: AMGN) today announced new data in patients with high unmet need, providing further evidence of the efficacy ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles